Business Context and Reporting Period
Autolus Therapeutics plc, a foreign private issuer incorporated in England and Wales, filed this Form 6-K on September 26, 2018. The company underwent a corporate reorganization in June 2018, transitioning from Autolus Therapeutics Limited to a public limited company structure. This filing furnishes unaudited financial statements for the period ended March 31, 2018, which predate the June 2018 reorganization and initial public offering.
Key Financial Metrics
The filing text references the existence of unaudited balance sheets and statements of operations but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of the report. The financial data is contained in Exhibits 99.1, 99.2, and 99.3, which are not included in the provided text.
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The primary material change disclosed is the corporate reorganization completed in June 2018. This involved Autolus Therapeutics Limited becoming the direct holding company of a new entity, Autolus Holdings (UK) Limited, and subsequently re-registering as Autolus Therapeutics plc. The financial statements furnished in this report do not reflect the impact of this reorganization or the subsequent initial public offering.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details regarding contingencies. The report serves strictly to furnish historical unaudited financial statements as exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 for the unaudited balance sheet of Autolus Therapeutics plc as of March 31, 2018.
- Review Exhibit 99.2 for the unaudited condensed balance sheets of the predecessor entity, Autolus Limited.
- Review Exhibit 99.3 for the unaudited condensed statements of operations and comprehensive loss for the six months ended March 31, 2018 and 2017.
- Verify the impact of the June 2018 corporate reorganization and IPO on the company's current capital structure, as the furnished data predates these events.